Also, in a second analysis of NeoALTTO clinical trial which aimed to quantify gene expression levels of ESR1 and HER2 and their relation to pCR, it was revealed that high levels of HER2 and low levels of ESR1 were associated with higher pCR rates [68] They explained these findings based on the increasing amount of genomic and clinical data reporting that HER2-overexpressing tumours have distinct molecular and clinical profiles [67] and that the HER2-E subtype, which is predominantly ER-negative, achieved higher response to HER2-directed therapy [69]. The gene discussed is ESR1; the disease is neoplasm.